Business
Enzolytics Announces Progress in the Development and Patenting of Feline Leukemia Monoclonal Antibodies
Enzolytics Announces Progress in the Development and Patenting of Feline Leukemia Monoclonal Antibodies.
About this update from Enzolytics Inc.
[{"type":"text","content":"COLLEGE STATION, TX / ACCESSWIRE / April 4, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/).Enzolytics today announced progress on its ongoing program to produce Monoclonal Antibodies to treat animals by filing a comprehensive patent application covering its identification of conserved neutralizable epitopes on the Feline Leukemia (FeLV) virus. Using the Company's Artificial Intelligence technology, more than 26 immutable epitope sites on the FeLV virus have been identified. These sites are claimed in the filed patent application. The patent covers the use of any of its discovered numerous conserved Feline Leukemia epitopes in the production of monoclonal antibodies, the production of vaccines, or use in diagnostic tests for detecting the virus in cats. The Company's wholly owned subsidiary Biogenysis, Inc. holds the exclusive license to this technology and manages this technology field for the Company.While the Company's focus is on producing monoclonal antibodies for treating numerous human viruses, including COVID-19, HIV, HIV-2, Influenza A and B, H1N1 influenza, Respiratory syncytial virus (RSV), Small-Pox, Ebola Virus, Tetanus, Diphtheria, HTLV-1/2, Rabies, Herpes zoster, Varicella zoster, Anthrax, Mason-Pfizer monkey virus (MPMV) and Visna virus (VISNA), the Company has also analyzed epitopes of animal viruses, namely the Cat Feline Leukemia Virus (FeLV), Horse Equine Infectious Anemia Virus, Chicken Anemia Virus, Koala Retrovirus (KoRV), Elephant Endotheliotropic Herpes Virus (EEHV), Avian Flu Swine Flu, This analysis has revealed the conserved immutable sites on these viruses against which monoclonal antibody production is planned. The findings will ultimately be claimed in U.S. and foreign patent applications.Targeting the conserved sites discovered by Enzolytics allows the production of a therapeutic that will not be rendered ineffective due to mutation (variants) of the virus. Even a "variant form of the virus" will contain the immutable targeted sites. Targeting immutable sites avoids the ineffectiveness that is experienced when a therapeutics or vaccine targets a site that has mutated.Currently, there is no cure for Cat Feline Leukemia (FeLV) virus. The cost of treatment of the virus is significant. There are more than 45 million cats in the U.S. and over 25% of households in America own...